The use of PDE-5 inhibitors increased significantly after November 2016 (2.1% prior vs. 3.4% after; p = 0.02), likely reflecting the national approval of this therapy for PAH treatment in Serbia. Here, PDE5A is linked to pulmonary arterial hypertension.